Proteins and Peptides

01 Feb 2017 Catalyst Biosciences Announces Positive Preclinical Data of Subcutaneously Dosed Coagulation Factors VIIa and IX at EAHAD Annual Congress
31 Jan 2017 Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
27 Jan 2017 Foresee Pharmaceuticals Announces Top-Line Results from Phase 3 Registration Study in Advanced Prostate Cancer
21 Jan 2017 ARMO BioSciences Presents New Phase 1b Clinical Data for AM0010 in Advanced Pancreatic Cancer Patients at 2017 Gastrointestinal Cancers Symposium
21 Jan 2017 Synergy Pharmaceuticals’ TRULANCE™ (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
19 Jan 2017 Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017
18 Jan 2017 BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
18 Jan 2017 Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis
18 Jan 2017 SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes
12 Jan 2017 First patient randomised in a phase II study evaluating safety and efficacy of anakinra in the treatment of acute gout
09 Jan 2017 AFSTYLA®, for Haemophilia A, Receives European Commission Approval
09 Jan 2017 Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe
07 Jan 2017 Enzyvant to Develop Novel Biologic Therapy for Complete DiGeorge Syndrome
07 Jan 2017 Okogen Secures Ora® to Conduct Clinical and Regulatory Development of OKG-0301 for Adenoviral Conjunctivitis
07 Jan 2017 Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
07 Jan 2017 LFB S.A. Announced Today the Acceptance by U.S. Food and Drug Administration of the Filed Biologic License Application for Coagulation Factor VIIa Recombinant, (eptacog beta activated)
05 Jan 2017 Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
05 Jan 2017 XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome
05 Jan 2017 Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol® in Adults with Moderate to Severe Dry Eye Disease
05 Jan 2017 Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints
05 Jan 2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
04 Jan 2017 Tarveda Therapeutics Announces Phase 1/2a Clinical Trial of PEN-221 Underway in Patients with Neuroendocrine Tumors and Small Cell Lung Cancer
04 Jan 2017 Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye
01 Jan 2017 OPKO Health Provides Update on hGH-CTP Clinical Programs
29 Dec 2016 Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing